scorecardresearch Skip to main content
Health and biotech

Latest stories

AbbVie buying Cambridge biotech Cerevel for $8.7 billion

The deal comes less than a week after the Illinois-based pharmaceutical giant said it would acquire ImmunoGen of Waltham for more than $10 billion.

New England Sinai rehab hospital in Stoughton will close
Steward Health Care’s move puts more pressure on hospitals in the region that have struggled to discharge patients.

Beth Teitell | Commentary
A nation twisting with anxiety is willing to try anything. A bed of nails? Hypnosis? A cold plunge? Bring ‘em on.
The bad news is that the nation is swirling in an epidemic of nerves. The good news is that there’s an industry eager to monetize our distress.

Nurse shortages are set to get even worse with mass US visa delays
Experts estimate that at least 10,000 foreign nurses have been delayed indefinitely — a holdup that's almost certain to worsen an already dire national shortage.

RI HEALTH CARE
CVS to launch new pharmacy reimbursement model aimed at simplifying drug pricing
CVS Health Corp. plans to change how its more than 9,000 pharmacies get paid with a new reimbursement model designed to simplify drug pricing.

Mass. families watch as Supreme Court questions Sackler shield in Purdue’s opioid settlement
A provision that would shield the wealthy Sacklers from future litigation has divided families who have lost loved ones to opioid overdoses.

Featured stories

How a Boston doctor diagnosed the first US case of monkeypox

After a few days, the doctor noticed a telling change. The patient’s rash consisted of fluid-filled blisters that had a dent in the center. His rash looked like smallpox.

Once the ‘it’ supplement, vitamin D is losing its sparkle

Vitamin D supplements, regularly consumed by millions of Americans, have not held up to the considerable hype of warding off many common, dreaded diseases.

Right-wing groups hit Boston Children’s with barrage of threats over trans health program

A hostile online campaign has prompted the hospital to seek help from law enforcement.

This startup aims to delay menopause and prolong fertility with a new contraceptive

Oviva Therapeutics just raised $11.5 million to develop drugs based on the work of Mass. General researchers.
Biotech

AbbVie buying Cambridge biotech Cerevel for $8.7 billion

The deal comes less than a week after the Illinois-based pharmaceutical giant said it would acquire ImmunoGen of Waltham for more than $10 billion.

EyePoint data suggest time-released drug may help patients with macular degeneration

EyePoint’s stock price vaulted more than 180 percent to $18.56 a share, a gain of $11.90 on the Nasdaq exchange in mid-day trading.
INNOVATOR Q&A

Many Americans ration insulin to save money. One nonprofit is trying to make the life-saving drug more affordable.

Eric Moyal is the founder and executive director of Project Insulin, a Providence-based nonprofit working to ensure that every American has access to affordable insulin.
Lifestyle
RI HEALTH CARE

CVS to launch new pharmacy reimbursement model aimed at simplifying drug pricing

CVS Health Corp. plans to change how its more than 9,000 pharmacies get paid with a new reimbursement model designed to simplify drug pricing.
INNOVATOR Q&A

Many Americans ration insulin to save money. One nonprofit is trying to make the life-saving drug more affordable.

Eric Moyal is the founder and executive director of Project Insulin, a Providence-based nonprofit working to ensure that every American has access to affordable insulin.
RI NEWS

Majority of R.I. residents say cost of living is becoming harder to afford, according to survey

The availability of affordable housing, services for children, access to health care and food security, and jobs were among the key issues, according to the 2023 Rhode Island Life Index.
Spotlight

How Brigham Health helped create a Chinese hospital for elites — and almost nobody came

In a deal worth millions with Chinese developer Evergrande, a Harvard teaching hospital risked its reputation on what would become a near-empty shell.

Boston’s hospital chiefs moonlight on corporate boards at rates far beyond the national level

Hospital chiefs and trustees defend this as boosting public-private partnerships, but critics say these board positions — some paying millions of dollars — raise troubling issues of conflict of interest and hospital priorities.

More biotech and health care stories

EyePoint data suggest time-released drug may help patients with macular degeneration

EyePoint’s stock price vaulted more than 180 percent to $18.56 a share, a gain of $11.90 on the Nasdaq exchange in mid-day trading.

INNOVATOR Q&A

Many Americans ration insulin to save money. One nonprofit is trying to make the life-saving drug more affordable.

Eric Moyal is the founder and executive director of Project Insulin, a Providence-based nonprofit working to ensure that every American has access to affordable insulin.

Local vets urge caution but not panic over ‘mystery’ respiratory illness found in dogs

Boston-area veterinarians said they have received a surge of calls from concerned dog owners following media reports about the “mystery illness,” which in some cases has developed into pneumonia and even led to death.

FDA poised to approve first gene-editing therapy, made by local drug firms

The life-changing drug, developed by Boston-based Vertex and its Swiss partner CRISPR Therapeutics, targets sickle cell disease, an inherited blood disorder that causes crippling pain.

COVID levels in waste water edge up post-Thanksgiving

But the numbers remain low relative to this time last year.

What’s your risk of dementia? Tool from Mass. General helps assess brain health.

New research suggests a high score on measures of physical health, lifestyle, and social life translates to a lower risk of some brain diseases.

AbbVie strikes deal to acquire Waltham’s ImmunoGen for more than $10 billion

It’s the largest acquisition of a Massachusetts company this year.

Generation Bio cuts its payroll by 40 percent in latest restructuring move

The Cambridge biotech startup is seeking to extend its cash into 2027.